Recruiting
Phase 1
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
About this study
This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)
- Condition
- ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
- Tested
- NXP900, Lorlatinib
- Sponsor
- Nuvectis Pharma, Inc.
Who can join
- Age
- Not specified
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 6
- Study condition: ALK Positive, ALK Positive Non-small Cell Lung Cancer, NSCLC, ALK+ Non-Small-Cell Lung Carcinoma
- 18 years old or older
- Unresectable, metastatic or locally advanced ALK-positive NSCLC.
- Must have received lorlatinib as first or second line TKI
- One prior line of systemic chemotherapy is permitted
- Must have tolerated the dose level of lorlatinib actively being explored in the study or a higher dose
Exclusion 2
- Known single or compound ALK domain mutations that cause resistance to lorlatinib, or known actionable oncogenic driver alterations other than ALK with approved targeted therapies available, such as, MET or EGFR mutations or HER2 overexpression
- Any contraindications to treatment with lorlatinib according to the lorlatinib United States Prescribing Information (USPI)
Where
1 site, 1 recruiting
NEXT Virginia
Fairfax, Virginia, United States
Contact
-
Erin Belshaw
2016278129 ebelshaw@nuvectis.com
-
Shay Shemesh
Potential match only. Final eligibility is determined by the study team.